if subject be not currently receive a tricyclic antidepressant anticonvulsant and/or class i antiarrhythmic e.g. amitriptyline mexiletine phenytoin gabapentin or carbamazepine for treatment of pain or any other condition subject must be willing and able to abstain from initiation of these agent within 4 week prior to randomization and throughout the study 